Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Date: July 2, 2012
Context: GSK announced the conclusion of a previously announced agreement in principle to resolve multiple investigations with the US Government, numerous states, and the District of Columbia. The settlement addresses criminal and civil liabilities regarding sales and marketing practices, Medicaid Rebate Program pricing, and Avandia regulatory submissions.
Key Financial Metrics
- Settlement Amount: $3 billion total payments.
- Funding Source: Existing cash resources.
- Provision Status: The $3 billion settlement is covered by existing legal provisions announced in November 2011.
- Q2 2012 Tax Impact: A credit of approximately $150 million (after-tax) will be recorded to the non-core tax charge because the final cost is lower than previously provided.
- Q2 2012 SG&A Impact: An additional pre-tax provision of approximately $180 million (equating to an after-tax cost of $150 million) will be recorded as a non-core charge in SG&A due to evolving state litigation.
- Net Earnings Impact: The net effect of these movements on total earnings is expected to be neutral.
Note: The filing does not provide specific figures for revenue, profit, cash flow, margins, debt, or liquidity for the period.
Material Changes and Settlement Details
The agreement resolves long-standing investigations initiated as early as 2004. Key components include:
- Criminal Plea: GSK will plead guilty to misdemeanor violations of the Federal Food, Drug, and Cosmetic Act related to the marketing of Paxil (paediatric use) and Wellbutrin (certain uses), and for failure to include information on Avandia studies in FDA reports.
- Civil Settlement: Does not constitute an admission of liability for the selling and marketing of Lamictal, Zofran, Imitrex, Lotronex, Flovent, Valtrex, Avandia, or Advair, nor for nominal pricing practices.
- Corporate Integrity Agreement (CIA): GSK entered into a CIA with the Office of Inspector General (OIG) covering US compliance, marketing, selling, and a portion of manufacturing operations related to a 2010 settlement regarding a Puerto Rico facility.
Management Commentary, Risks, and Outlook
Management Commentary: CEO Sir Andrew Witty stated that the resolution addresses matters from a "different era" and expressed regret for past mistakes. He emphasized a cultural shift since his appointment to prioritize patients, transparency, and integrity.
Operational Changes:
- Fundamental changes to US compliance, marketing, and selling procedures have been implemented.
- Employees engaged in misconduct have been removed.
- Since January 2011, a new incentive compensation system for sales representatives eliminates individual sales targets, focusing instead on service quality and patient health.
- Enhanced ability to "claw back" senior management remuneration.
Risks and Contingencies:
- The company notes that forward-looking statements are subject to risks and uncertainties.
- While the federal settlement is resolved, the company expects to utilize tax benefits to offset an additional provision related to the "evolving state litigation environment."
Investor Verification Checklist
- Verify that the $3 billion settlement is fully covered by existing provisions and does not require new capital allocation.
- Confirm the net neutral impact on Q2 2012 earnings by reviewing the offset between the tax credit and the SG&A charge.
- Review the terms of the Corporate Integrity Agreement (CIA) to understand ongoing compliance obligations and potential penalties for future violations.
- Monitor the "evolving state litigation environment" for potential additional provisions beyond the $180 million estimated charge.
- Assess the effectiveness of the new sales representative compensation model in aligning with regulatory expectations.